Digestive physiology of the pig symposium: Intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways

Journal of Animal Science

Volumn 91, Issue 5, 2013, Pages 1991-2000

  Burrin, D ^a   Stoll, B ^a   Moore, D ^b  

^a USDA Children's Nutrition Research Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Enteroendocrine; Farnesoid X receptor; Fibroblast growth factor 19; G protein coupled bile acid receptor 1 TGR5; Glucagon like peptide 1; Glucagon like peptide 2

Indexed keywords

EID: 84882570594     PISSN: 00218812     EISSN: 15253163     Source Type: Journal    
DOI: 10.2527/jas.2013-6331     Document Type: Article

References (70)

1. Al-Mukhtar, M. Y., G. R. Sagor, M. A. Ghatei, S. R. Bloom, and N. A. Wright. 1983. The role of pancreatico-biliary secretions in intestinal adaptation after resection, and its relationship to plasma enteroglucagon. Br. J. Surg. 70:398-400.
2. Baggio, L. L., and D. J. Drucker. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
3. Baghdasaryan, A., T. Claudel, J. Gumhold, D. Silbert, L. Adorini, A. Roda, S. Vecchiotti, F. J. Gonzalez, K. Schoonjans, M. Strazzabosco, P. Fickert, and M. Trauner. 2011. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology 54:1303-1312.
4. Barrera, J. G., D. A. Sandoval, D. A. D'Alessio, and R. J. Seeley. 2011. GLP-1 and energy balance: An integrated model of shortterm and long-term control. Nat. Rev. Endocrinol. 7:507-516.
5. Beysen, C., E. J. Murphy, K. Deines, M. Chan, E. Tsang, A. Glass, S. M. Turner, J. Protasio, T. Riiff, and M. K. Hellerstein. 2012. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study. Diabetologia 55:432-442.
6. Burrin, D. G., B. Stoll, and X. Guan. 2003. Glucagon-like peptide 2 function in domestic animals. Domest. Anim. Endocrinol. 24:103-122.
7. Burrin, D. G., B. Stoll, R. Jiang, X. Chang, B. Hartmann, J. J. Holst, G. H. Greeley Jr., and P. J. Reeds. 2000a. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: How much is enough? Am. J. Clin. Nutr. 71:1603-1610.
8. Burrin, D. G., B. Stoll, R. Jiang, Y. Petersen, J. Elnif, R. K. Buddington, M. Schmidt, J. J. Holst, B. Hartmann, and P. T. Sangild. 2000b. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G1249-G1256.
9. Chambers, A. P., M. A. Stefater, H. E. Wilson-Perez, L. Jessen, S. Sisley, K. K. Ryan, S. Gaitonde, J. E. Sorrell, M. Toure, J. Berger, D. A. D'Alessio, D. A. Sandoval, R. J. Seeley, and S. C. Woods. 2011. Similar effects of roux-en-Y gastric bypass and vertical sleeve gastrectomy on glucose regulation in rats. Physiol. Behav. 105:120-123.
10. Cipriani, S., A. Mencarelli, M. G. Chini, E. Distrutti, B. Renga, G. Bifulco, F. Baldelli, A. Donini, and S. Fiorucci. 2011. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis.PLoS. One 6:e25637.
11. Dawson, P. A., M. L. Hubbert, and A. Rao. 2010. Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochim. Biophys. Acta 1801:994-1004.
12. Drucker, D. J. 2005. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metab. 1:22-31.
13. Drucker, D. J. 2006. The biology of incretin hormones. Cell Metab. 3:153-165.
14. Dube, P. E., and P. L. Brubaker. 2004. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm. Metab. Res. 36:755-760.
15. Dyer, J., K. Daly, K. S. Salmon, D. K. Arora, Z. Kokrashvili, R. F. Margolskee, and S. P. Shirazi-Beechey. 2007. Intestinal glucose sensing and regulation of intestinal glucose absorption. Biochem. Soc. Trans. 35:1191-1194.
16. Estall, J. L., and D. J. Drucker. 2006. Glucagon-like peptide-2. Annu. Rev. Nutr. 26:391-411.
17. Fiorucci, S., E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, L. Riccardi, S. Orlandi, R. Pellicciari, and A. Morelli. 2004. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497-1512.
18. Fiorucci, S., C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, B. M. Sadeghpour, G. Sabatino, G. Russo, D. Castellani, T. M. Willson, M. Pruzanski, R. Pellicciari, and A. Morelli. 2005. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313:604-612.
19. Fiorucci, S., A. Mencarelli, G. Palladino, and S. Cipriani. 2009. Bileacid-activated receptors: Targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30:570-580.
20. Fu, L., L. M. John, S. H. Adams, X. X. Yu, E. Tomlinson, M. Renz, P. M. Williams, R. Soriano, R. Corpuz, B. Moffat, R. Vandlen, L. Simmons, J. Foster, J. P. Stephan, S. P. Tsai, and T. A. Stewart. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594-2603.
21. Gaitonde, S., R. Kohli, and R. Seeley. 2012. The role of the gut hormone GLP-1 in the metabolic improvements caused by ileal transposition. J. Surg. Res. 178:33-39.
22. Genet, C., A. Strehle, C. Schmidt, G. Boudjelal, A. Lobstein, K. Schoonjans, M. Souchet, J. Auwerx, R. Saladin, and A. Wagner. 2010. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes. J. Med. Chem. 53:178-190.
23. Hofmann, A. F., and L. R. Hagey. 2008. Bile acids: Chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol. Life Sci. 65:2461-2483.
24. Holst, J. J., and M. A. McGill. 2012. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: Focus on bile acid sequestrants. Clin. Drug Investig. 32:1-14.
25. Huang, X., C. Yang, Y. Luo, C. Jin, F. Wang, and W. L. McKeehan. 2007. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56:2501-2510.
26. Jain, A. K., B. Stoll, D. G. Burrin, J. J. Holst, and D. D. Moore. 2012. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G218-G224.
27. Kawamata, Y., R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, and M. Fujino. 2003. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278:9435-9440.
28. Kim, I., S. H. Ahn, T. Inagaki, M. Choi, S. Ito, G. L. Guo, S. A. Kliewer, and F. J. Gonzalez. 2007. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48:2664-2672.
29. Kindel, T. L., S. M. Yoder, R. J. Seeley, D. A. D'Alessio, and P. Tso. 2009. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J. Gastrointest. Surg. 13:1762-1772.
30. Kir, S., S. A. Beddow, V. T. Samuel, P. Miller, S. F. Previs, K. Suino-Powell, H. E. Xu, G. I. Shulman, S. A. Kliewer, and D. J. Mangelsdorf. 2011. FGF19 as a postprandial, insulinindependent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624.
31. Kuro-O, M. 2008. Endocrine FGFs and Klothos: Emerging concepts.Trends Endocrinol. Metab. 19:239-245.
32. Lan, T., A. Rao, J. Haywood, N. D. Kock, and P. A. Dawson. 2012. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. J. Hepatol. 57:359-365.
33. le Roux, C. W., C. Borg, K. Wallis, R. P. Vincent, M. Bueter, R. Goodlad, M. A. Ghatei, A. Patel, S. R. Bloom, and S. J. Aylwin. 2010. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann. Surg. 252:50-56.
34. Lefebvre, P., B. Cariou, F. Lien, F. Kuipers, and B. Staels. 2009. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89:147-191.
35. Li, T., S. R. Holmstrom, S. Kir, M. Umetani, D. R. Schmidt, S. A. Kliewer, and D. J. Mangelsdorf. 2011. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 25:1066-1071.
36. Lovshin, J. A., and D. J. Drucker. 2009. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5:262-269.
37. Lundasen, T., C. Galman, B. Angelin, and M. Rudling. 2006. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260:530-536.
38. May, C. L., and K. H. Kaestner. 2010. Gut endocrine cell development. Mol. Cell. Endocrinol. 323:70-75.
39. Mencarelli, A., B. Renga, M. Migliorati, S. Cipriani, E. Distrutti, L. Santucci, and S. Fiorucci. 2009. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183:6657-6666.
40. Meschere, A. L. 2010. Junqueira's basic histology: Text and atlas, 12th Edition. McGraw-Hill Companies, Inc., Columbus, OH.
41. Mingrone, G., S. Panunzi, G. A. De, C. Guidone, A. Iaconelli, L. Leccesi, G. Nanni, A. Pomp, M. Castagneto, G. Ghirlanda, and F. Rubino. 2012. Bariatric surgery versus conventional medical therapy for type 2 diabetes. New Engl. J. Med. 366:1577-1585.
42. Modica, S., M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, T. G. Di, G. Palasciano, T. Moustafa, E. Halilbasic, M. Trauner, and A. Moschetta. 2012. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142:355-365.
43. Parker, H. E., K. Wallis, C. W. le Roux, K. Y. Wong, F. Reimann, and F. M. Gribble. 2012. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165:414-423.
44. Parks, D. J., S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. A. Kliewer, J. B. Stimmel, T. M. Willson, A. M. Zavacki, D. D. Moore, and J. M. Lehmann. 1999. Bile acids: Natural ligands for an orphan nuclear receptor. Science 284:1365-1368.
45. Pellicciari, R., G. Costantino, E. Camaioni, B. M. Sadeghpour, A. Entrena, T. M. Willson, S. Fiorucci, C. Clerici, and A. Gioiello. 2004. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem. 47:4559-4569.
46. Pellicciari, R., A. Gioiello, A. Macchiarulo, C. Thomas, E. Rosatelli, B. Natalini, R. Sardella, M. Pruzanski, A. Roda, E. Pastorini, K. Schoonjans, and J. Auwerx. 2009. Discovery of 6alphaethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52:7958-7961.
47. Potthoff, M. J., S. A. Kliewer, and D. J. Mangelsdorf. 2012. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 26:312-324.
48. Potthoff, M. J., A. Potts, T. He, J. A. Duarte, R. Taussig, D. J. Mangelsdorf, S. A. Kliewer, and S. C. Burgess. 2013. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 304:G371-G380.
49. Pournaras, D. J., C. Glicksman, R. P. Vincent, S. Kuganolipava, J. Alaghband-Zadeh, D. Mahon, J. H. Bekker, M. A. Ghatei, S. R. Bloom, J. R. Walters, R. Welbourn, and C. W. le Roux. 2012. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153:3613-3619.
50. Rainey, J. B., P. W. Davies, J. B. Bristol, and R. C. Williamson. 1983. Adaptation and carcinogenesis in defunctioned rat colon: Divergent effects of faeces and bile acids. Br. J. Cancer 48:477-484.
51. Rainey, J. B., M. Maeda, and R. C. Williamson. 1986. The tropic effect of intrarectal deoxycholate on rat colorectum is unaffected by oral metronidazole. Cell Tissue Kinet. 19:485-490.
52. Raybould, H. E. 2010. Gut chemosensing: Interactions between gut endocrine cells and visceral afferents. Auton. Neurosci. 153:41-46.
53. Raybould, H. E., J. Glatzle, S. L. Freeman, K. Whited, N. Darcel, A. Liou, and D. Bohan. 2006. Detection of macronutrients in the intestinal wall. Auton. Neurosci. 125:28-33.
54. Reimann, F., A. M. Habib, G. Tolhurst, H. E. Parker, G. J. Rogers, and F. M. Gribble. 2008. Glucose sensing in L cells: A primary cell study. Cell Metab. 8:532-539.
55. Rizzo, G., D. Passeri, F. F. De, G. Ciaccioli, L. Donadio, G. Rizzo, S. Orlandi, B. Sadeghpour, X. X. Wang, T. Jiang, M. Levi, M. Pruzanski, and L. Adorini. 2010. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78:617-630.
56. Rowland, K. J., and P. L. Brubaker. 2011. The "cryptic" mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 301:G1-G8.
57. Rubino, F., S. L. R'bibo, F. del Genio, M. Mazumdar, and T. E. McGraw. 2010. Metabolic surgery: The role of the gastrointestinal tract in diabetes mellitus. Nat. Rev. Endocrinol. 6:102-109.
58. Ryan, K. K., R. Kohli, R. Gutierrez-Aguilar, S. G. Gaitonde, S. C. Woods, and R. J. Seeley. 2013. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154:9-15.
59. Savage, A. P., M. S. Sian, J. L. Matthews, S. R. Bloom, and T. Cooke. 1988. Experimental colonic carcinogenesis: Changes in faecal bile acids after promotion of intestinal tumours by small bowel resection in the rat. Gut 29:495-502.
60. Shang, Q., M. K. Liu, M. Saumoy, J. J. Holst, G. Salen, and G. Xu. 2012. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G815-G823.
61. Shang, Q., M. Saumoy, J. J. Holst, G. Salen, and G. Xu. 2010. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298:G419-G424.
62. Stoll, B., D. A. Horst, L. Cui, X. Chang, K. J. Ellis, D. L. Hadsell, A. Suryawan, A. Kurundkar, A. Maheshwari, T. A. Davis, and D. G. Burrin. 2010. Chronic parenteral nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal pigs. J. Nutr. 140:2193-2200.
63. Stoll, B., P. J. Puiman, L. Cui, X. Chang, N. M. Benight, C. Bauchart-Thevret, B. Hartmann, J. J. Holst, and D. G. Burrin. 2012. Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs. JPEN J. Parenter. Enteral Nutr. 36:538-550.
64. Thomas, C., A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, and K. Schoonjans. 2009. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167-177.
65. Thomas, C., R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans. 2008. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7:678-693.
66. Tomlinson, E., L. Fu, L. John, B. Hultgren, X. Huang, M. Renz, J. P. Stephan, S. P. Tsai, L. Powell-Braxton, D. French, and T. A. Stewart. 2002. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747.
67. Unger, R. H., A. Ohneda, I. Valverde, A. M. Eisentraut, and J. Exton. 1968. Characterization of the responses of circulating glucagonlike immunoreactivity to intraduodenal and intravenous administration of glucose. J. Clin. Invest. 47:48-65.
68. van Goudoever, J. B., B. Stoll, B. Hartmann, J. J. Holst, P. J. Reeds, and D. G. Burrin. 2001. Secretion of trophic gut peptides is not different in bolus- and continuously fed piglets. J. Nutr. 131:729-732.
69. Wang, H., J. Chen, K. Hollister, L. C. Sowers, and B. M. Forman. 1999. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3:543-553.
70. Xiao, Q., R. P. Boushey, D. J. Drucker, and P. L. Brubaker. 1999. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117:99-105.